Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Definium Therapeutics, Inc.

Definium Therapeutics, Inc. (DFTX) Stock Overview

Explore Definium Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

DFTX●NASDAQ
HealthcareBiotechnology
$37.40
$0.20(0.53%)
U.S. Market opens in 0h 24m

Definium Therapeutics, Inc. (DFTX)

Meyka AI Score

Z

Key Financials

Market Cap5B
P/E Ratio-10.76
EPS (TTM)N/A
ROE-0.85%
Fundamental Analysis

AI Price Forecasts

1 Month$45.35
3 Months$48.25
1 Year Target$51.75

DFTX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Definium Therapeutics, Inc. (NASDAQ: DFTX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Definium Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of DFTX on the NASDAQ shows an RSI of 42.95, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $51.75 for the NASDAQ listing.

Key metrics behind Definium Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -10.76 and a market capitalization of 5B. Combined with our AI analysis, these give both institutional and retail investors a clear view of DFTX on the NASDAQ.

Price Performance (NASDAQ: DFTX)

1-Day Change
-0.53%
5-Day Change
1.08%
1-Month Change
-3.86%
3-Month Change
-15.37%
6-Month Change
80.85%
Year-to-Date (YTD) Change
179.31%
1-Year Change
206.06%
3-Year Change
1122.22%
5-Year Change
12.31%
All-Time (Max) Change
1006.51%

Contact Information

https://definiumtx.com
212 220 6633
One World Trade Center, New York, NY, 10007

Company Facts

1,060 Employees
IPO DateNov 15, 2016
CountryUS
Actively Trading

Frequently Asked Questions